TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products, is pleased to announce Nick Hilborn, CPA, CA, Vice President of Finance, is appointed Interim Chief Financial Officer, following Phillip Cardella, CPA, CA, transition to consultant effective Monday, September 15, 2025. “We thank Phil for his contri ...

Core Insights - The United States Patent and Trademark Office (USPTO) has issued Patent No. US 12,343,315 B2 to Avicanna Inc. for its topical cannabinoid compositions aimed at promoting clear skin [1][2] - The patent covers a topical gel formulation that combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents, targeting skin diseases such as acne, wrinkles, rosacea, and erythema [2] - Avicanna's CEO expressed enthusiasm about the patent, highlighting its potential in the company's commercial platforms and pharmaceutical pipeline [3] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4] - The company has a robust scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products [4] - Avicanna operates multiple business pillars, including a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and a subsidiary (Santa Marta Golden Hemp SAS) that supplies active pharmaceutical ingredients [4][7]

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brok ...

Core Viewpoint - Avicanna Inc. has successfully closed a non-brokered private placement offering, raising $1,000,000 through the sale of 4,000,000 units at a price of $0.25 per unit, which includes common shares and warrants [1][2]. Group 1: Offering Details - The offering consists of 4,000,000 units priced at $0.25 each, resulting in total gross proceeds of $1,000,000 [1]. - Each unit includes one common share and one-half of a common share purchase warrant, with the warrants allowing the purchase of additional shares at an exercise price of $0.30 until July 16, 2028 [1]. - The securities from the offering are subject to a four-month hold period under Canadian securities laws and require necessary approvals, including from the Toronto Stock Exchange [3]. Group 2: Use of Proceeds - The proceeds from the offering will be allocated for general working capital, administrative expenses, production and manufacturing costs, and research and clinical development [2]. Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4]. - The company has a scientific platform that supports over thirty proprietary products and operates four commercial-stage business pillars [4]. - Avicanna's product offerings include a diverse range of cannabinoid-based formulations and a medical cannabis care platform aimed at enhancing patient support and education [6].

Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-base ...

Core Insights - Avicanna Inc. has reported its first profitable quarter in Q1 2025, marking a significant milestone for the company [1][2][7] Financial Highlights - The company achieved a net income of $74,154 and a comprehensive income of $876,092, attributed to cost efficiencies and margin improvements [7] - Adjusted positive EBITDA was approximately $431,000, a substantial increase from about $18,000 in Q1 2024 [7] - Gross profit reached $3.54 million, reflecting a 7% year-over-year increase, with consolidated gross margins improving to 56% from 51% in Q1 2024 [7] - Revenue for the quarter was $6.32 million, a slight 2% decrease compared to Q1 2024, alongside a 5% reduction in general and administrative expenses [7] Corporate Developments - Avicanna expanded its Canadian portfolio to 42 proprietary commercial SKUs, a 35% increase from 31 SKUs in the same period in 2024, while maintaining a total of 135 commercial listings [4] - The company announced a scientific and medical affairs collaboration with Aspeya to enhance research and medical initiatives related to medical cannabis in Canada [5] Product and Service Offerings - The RHO Phyto™ formulary includes a diverse range of proprietary products with various cannabinoid delivery methods, supported by ongoing education for patients and the medical community [8] - MyMedi.ca serves as a medical cannabis care platform aimed at improving patient access and support, featuring a diverse product portfolio and specialty services for distinct patient groups [9] Research and Development - Avicanna is advancing a pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [12] - The company’s majority-owned subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality CBD, THC, and CBG for various product developments [12]